Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gilbert, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gilbert, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2001) 47, 29-34
© 2001 The British Society for Antimicrobial Chemotherapy

Improving the outcome of facial resurfacing—prevention of herpes simplex virus type 1 reactivation

Stan Gilbert,*

Dermatology and Laser Center Northwest, 3614 Meridian, Suite #200, Bellingham, WA 98225, USA

Facial resurfacing is becoming an increasingly popular method of cosmetic surgery for improving the appearance of the skin on the face and neck. However, since the majority of the population is infected with herpes simplex virus type 1 (HSV-1) by adulthood, complications such as widespread facial lesions and post-operative scarring arising from reactivation of the virus can threaten the success of the procedure. Although there are no prospective controlled trials, oral antiviral therapy has been shown to be effective in preventing post-operative reactivation of HSV-1 when administered from a minimum of 2 h before surgery and continued up to 10 days thereafter. Since such therapies have very acceptable clinical safety profiles, it has become common practice for all individuals undergoing facial resurfacing to be treated with oral antivirals effective against HSV-1, regardless of their HSV-1 history or baseline serology.

1 *Tel: +1-360-676-4205; Fax: +1-360-676-0377; E-mail: scgilbert{at}hinet.org


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Anesth. Analg.Home page
P. W. Davies, M. C. Vallejo, K. T. Shannon, A. J. Amortegui, and S. Ramanathan
Oral Herpes Simplex Reactivation After Intrathecal Morphine: A Prospective Randomized Trial in an Obstetric Population
Anesth. Analg., May 1, 2005; 100(5): 1472 - 1476.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.